New studies show the benefits of biotech healthcare innovation for patients and society
The new version of the study BiOiMPACT released on the occasion of BioVision, the World Life Sciences Forum in Lyon, shows new positive findings about the impact of biotechnology on the treatment of a number of diseases that heavily affect millions of patients: breast cancer, cardio-vascular diseases, inflammatory bowel diseases and chronic inflammatory joint diseases.
The new findings clearly demonstrate that biotechnology provides major added-value in healthcare, in terms of:
- Better diagnosed, better treated and better cured patients;
- Improved efficiency and safety and reduced inefficiencies in the healthcare systems;
- Significant contribution to progress in science, medicine and societal and economic growth.
The study shows that only a minority of medicines derived from biotechnology are being developed in Europe, which indicates a weakness in Europe's ability to promote a pro-innovation policy framework.
"The patient testimonials and science-based information in these updated studies, presented in a clear and accessible manner are proof of the great contribution of biotech to address unmet medical needs. In order to guarantee continued access to the most innovative care, it is vital to create an optimal environment for the discovery and development of, as well as for patient access to biotech therapies in Europe," said Mr Andrea Rappagliosi, Chairman of EuropaBio's Healthcare Council.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Thermo Fisher Scientific and Intrinsic Bioprobes Announce Alliance in Mass Spectrometric Immunoassay (MSIA) Workflow Development
Farfield Scientific: Five New Patents Granted, Building on a Portfolio of Over 50 Applications Pending
North American Scientific Completes Sale of Non-Therapeutic Product Line
Beckman Coulter Announces the Creation of Beckman Coulter Genomics - New Company Offers Comprehensive Genomic Services
Bruker to acquire the NanoString business in an asset deal
Ultrasonic Scientific Expands its Operations with the Appointments of Italien and Japanese Distributors
DNTOX receives €1.4 million seed funding for non-animal testing of chemicals - The new capital will be used to set up the test laboratories in Düsseldorf, aim for GLP accreditation and launch the test battery on the market
Oxford Instruments announces major technology licensing deal with GE Healthcare - Result will be powerful new tool for in vitro molecular analysis
